|1.||Chen, Nianhang: 1 article (12/2004)|
|2.||Maiti, Soumen: 1 article (12/2004)|
|3.||Dutta, Aloke K: 1 article (12/2004)|
|4.||Zhen, Juan: 1 article (12/2004)|
|5.||Reith, Maarten E A: 1 article (12/2004)|
|6.||Morita, Katsuya: 1 article (02/2003)|
|7.||Kumagai, Kei: 1 article (02/2003)|
|8.||Kihira, Kenji: 1 article (02/2003)|
|9.||Kumagai, Michio: 1 article (02/2003)|
|10.||Arai, Shigeaki: 1 article (02/2003)|
|1.||Cocaine-Related Disorders (Cocaine Addiction)
12/03/2004 - "As a hydroxypiperidine analog of GBR 12935, (+)-R,R-D-84 is a candidate dopamine transporter compound for the treatment of cocaine dependence. "
10/01/2000 - "Gist-Brocades originally initiated studies of vanoxerine, along with another piperazine, GBR-12935, for the treatment of cocaine dependence. "
03/14/2002 - "In our search for long-acting agents for the treatment of cocaine abuse, a series of optically pure hydroxylated derivatives of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (1) and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine (2) (GBR 12909 and GBR 12935, respectively) were synthesized and evaluated in vitro and in vivo. "
12/02/1999 - "Oxygenated analogues of 1-[2-(Diphenylmethoxy)ethyl]- and 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as potential extended-action cocaine-abuse therapeutic agents."
12/02/1999 - "An investigation into the preparation of potential extended-release cocaine-abuse therapeutic agents afforded a series of compounds related to 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine (1a) and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (1b) (GBR 12935 and GBR 12909, respectively), which were designed, synthesized, and evaluated for their ability to bind to the dopamine transporter (DAT) and to inhibit the uptake of [(3)H]-labeled dopamine (DA). "
|2.||Parkinson Disease (Parkinson's Disease)
08/01/1987 - "The specific binding of [3H]GBR-12935 to membranes prepared from the caudate nuclei of patients with Parkinson's disease is decreased compared to membranes prepared from age- and sex-matched controls. "
11/08/1988 - "[3H]GBR 12935 binding was decreased in the putamen and caudate nucleus of subjects with Parkinson's disease (33 and 46% of control values, respectively) and progressive supranuclear palsy (38 and 57% of control values, respectively). "
08/01/1987 - "[3H]GBR-12935 binding to the dopamine transporter is decreased in the caudate nucleus in Parkinson's disease."
02/21/1994 - "The binding of [3H]GBR-12935 to dopamine (DA) uptake sites was studied in post-mortem putamen from a control group and from patients with Parkinson's disease (PD) or dementia of the Alzheimer type (DAT). "
11/08/1988 - "[3H]GBR 12935 binding to dopamine uptake sites: subcellular localization and reduction in Parkinson's disease and progressive supranuclear palsy."
01/01/1995 - "Kindling decreased the maximal number of [3H]GBR-12935 binding sites in the dorsal striatum of rats sacrificed either 2 h or 4 weeks after the last seizure but had no effect on stimulated fractional [3H]DA release. "
02/21/2003 - "Daily treatments of GBR 12935, a specific inhibitor of dopamine uptake, significantly increased the incidence and the intensity of lidocaine-induced convulsions at 20 mg/kg and decreased the threshold of the convulsions. "
|4.||Schizophrenia (Dementia Praecox)
02/01/1995 - "The results suggest a differential effect of age, or something associated with age, on [3H]GBR 12935 binding sites in the prefrontal cortex of controls and individuals with schizophrenia."
02/01/1995 - "[3H]GBR 12935 binding constants were calculated by Scatchard analysis from the autopsied brains from 29 individuals with schizophrenia, and 28 control subjects. "
01/01/1989 - "[3H] GBR 12935 binding to the dopamine uptake site in post-mortem brain tissue in schizophrenia."
|5.||Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy)
|1.||vanoxerine (I 893)
|4.||Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)